Market
Outcome of vaccine safety concerns for pregnancy by end of 2024?
2
Resolution / Starting Odds
Revised guidelines • 25%
Increased studies • 25%
No change • 25%
Other actions • 25%
Official health organization announcements and policy changes
Story
Family of Pregnant Woman Who Died Post-AstraZeneca Vaccine to Receive Over R$ 1 Million
Dec 7, 2024, 02:29 PM
The family of Thais Possati, a 35-year-old woman who was 23 weeks pregnant when she died shortly after receiving the AstraZeneca Covid-19 vaccine in April 2021, will receive over R$ 1 million in compensation. AstraZeneca has admitted that the vaccine was not tested on pregnant women. This case has raised concerns about the safety of vaccines for pregnant individuals, especially as the CDC recently recommended a novel Hepatitis B vaccine during pregnancy despite limited studies on its effects, including a retrospective cohort study of 75 women and a rat study.
View original story
Similar markets
Some vaccines recommended for elimination • 25%
No changes recommended • 25%
Comprehensive overhaul of vaccine policies • 25%
Enhanced safety protocols recommended • 25%
Minor issues found • 25%
No issues found • 25%
Undetermined • 25%
Significant issues found • 25%
Conduct further studies • 25%
No action taken • 25%
Other actions • 25%
Issue new safety guidelines • 25%
Guideline updates • 25%
No significant action • 25%
Further studies commissioned • 25%
Vaccine suspension or recall • 25%
Unchanged trust • 25%
No significant data • 25%
Increased trust • 25%
Decreased trust • 25%
Investigation not completed • 25%
No link found • 25%
Link found • 25%
Inconclusive results • 25%
Decreased Confidence • 25%
Increased Confidence • 25%
Other • 25%
No Change • 25%
Contamination confirmed, no recall • 25%
No significant contamination found • 25%
Investigation inconclusive • 25%
Contamination confirmed, recall issued • 25%
No changes to current vaccination program • 25%
Complete overhaul of vaccination program • 25%
Introduction of new vaccine safety measures • 25%
Reduction in number of vaccines • 25%
Mixed opinions • 25%
No change • 25%
Increase in support • 25%
Decrease in support • 25%
Vaccines not linked to autism • 25%
Inconclusive results • 25%
Investigation not completed • 25%
Vaccines linked to autism • 25%